Trial reportJournal of child and adolescent psychopharmacology2008
The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation.
Trial report in Journal of child and adolescent psychopharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01844700 (1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain), which is not on this map. Cited by 56 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain
Who cites it
56 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).The Cochrane database of systematic reviews · 2023Pooled it
- Evidence-based treatments for youths with severely dysregulated mood: a qualitative systematic review of trials for SMD and DMDD.European child & adolescent psychiatry · 2017Pooled it
- The Status of Irritability in Psychiatry: A Conceptual and Quantitative Review.Journal of the American Academy of Child and Adolescent Psychiatry · 2016Pooled it
- Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).The Cochrane database of systematic reviews · 2015Pooled it
- Trial
- A Double-Blind Randomized Placebo-Controlled Trial of Citalopram Adjunctive to Stimulant Medication in Youth With Chronic Severe Irritability.Journal of the American Academy of Child and Adolescent Psychiatry · 2020Trial
- The Effectiveness and Tolerability of Central Nervous System Stimulants in School-Age Children with Attention-Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder Across Home and School.Journal of child and adolescent psychopharmacology · 2016Trial
- A Randomized Clinical Trial of an Integrative Group Therapy for Children With Severe Mood Dysregulation.Journal of the American Academy of Child and Adolescent Psychiatry · 2016Trial
- Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder.Journal of child and adolescent psychopharmacology · 2015Trial
- A novel group therapy for children with ADHD and severe mood dysregulation.Journal of attention disorders · 2013Trial
- Trial
- Methylphenidate in mania project (MEMAP): study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate.BMC psychiatry · 2013Trial
- Early psychosocial intervention for youth at risk for bipolar I or II disorder: a one-year treatment development trial.Bipolar disorders · 2011Trial
- Co-occurring Symptoms of ADHD, Autism, Oppositional Defiant Disorder, and Academic Impairment in Referred and Community Children.Journal of psychopathology and behavioral assessment · 2026Article
- Article
- A Delphi consensus among experts on assessment and treatment of disruptive mood dysregulation disorder.Frontiers in psychiatry · 2023Article
- Frustration, Cognition, and Psychophysiology in Dysregulated Children: A Research Domain Criteria Approach.Journal of the American Academy of Child and Adolescent Psychiatry · 2022Article
- Executive Functioning and Emotion Regulation in Children with and without ADHD.Research on child and adolescent psychopathology · 2022Article
- Management of Emotion Dysregulation and Outbursts in Children and Adolescents.Current psychiatry reports · 2022Review
- Does central executive training and/or inhibitory control training improve emotion regulation for children with attention-deficit/hyperactivity disorder? A randomized controlled trial.Frontiers in psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectivesThis study examines the tolerability and efficacy of methylphenidate (MPH) and behavior modification therapy (BMOD) in children with attention-deficity/hyperactivity disorder (ADHD) and severe mood dysregulation (SMD).
methodsChildren (ages 5-12) from a summer program for ADHD were screened for SMD and additional manic-like symptoms using structured assessments and direct clinical interview with the Young Mania Rating Scale (YMRS). The SMD group was comprised of 33 subjects with SMD and elevated YMRS scores (mean = 23.7). They underwent weekly mood assessments plus the daily ADHD measures that are part of the program. The comparison group (n = 68) was comprised of the rest of the program participants. Using a crossover design, all subjects in both groups were treated with three varying intensities of BMOD (no, low, high) each lasting 3 weeks, with MPH dose (placebo, 0.15 mg/kg t.i.d., 0.3mg/kg t.i.d., and 0.6 mg/kg t.i.d.) varying daily within each behavioral treatment.
resultsGroups had comparable ADHD symptoms at baseline, with the SMD group manifesting more oppositional defiant disorder/conduct disorder (ODD/CD) symptoms (p < 0.001). Both groups showed robust improvement in externalizing symptoms (p < 0.001). There was no evidence of differential treatment efficacy or tolerability. Treatment produced a 34% reduction in YMRS ratings in SMD subjects (p - 0.001). However, they still exhibited elevated YMRS ratings, more ODD/CD symptoms (p < 0.001), and were more likely to remain significantly impaired at home than non-SMD subjects (p < 0.05).
conclusionsMPH and BMOD are tolerable and effective treatments for children with ADHD and SMD, but additional treatments may be needed to optimize their functioning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.